Additional phase II data backs up Bavarian Nordic's Covid-19 vaccine

Bavarian Nordic is on track with its plan to start phase III trials of its corona vaccine candidate in the first half of this year. New data released on Monday is promising for the candidate.

Photo: Philip Davali/Ekstra Bladet, Philip Davali

Danish biotech company Bavarian Nordic can once again announce positive results from a phase II study of its corona vaccine, ANBCoV2. The results from two remaining patient groups have now been analyzed and found to support the vaccine’s ability to boost neutralizing antibodies to levels that protect the individual against Covid-19.

Bavarian has previously reported of a strong boosting effect from its vaccine in a 100 mcg dose in people who had already received vaccine shots.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs